Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects

NCT02519270 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

62

Enrollment

INDUSTRY

Sponsor class

Stopped Strategic Reasons

Conditions

Non-Hodgkin Lymphoma

Interventions

BIOLOGICAL: IGN002

Sponsor

Spectrum Pharmaceuticals, Inc

Collaborators

[object Object]